57 min
Episode 103 Biotech Hangout
-
- Life Sciences
On this week’s Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Yaron Werber, Luba Greenwood and Dawn Bell start the show with a look at the XBI and M&A activity from the week, including multiple deals topping over $1 billion. The hosts highlight a few of these big transactions, including Biogen acquiring Hi-Bio for $1.15 billion, Merck acquiring Eyebio for $1.3 billion, J&J buying Yellow Jersey for $1.25 billion, and Novartis buying out Mariana for $1 billion, among others. With private acquisitions in the spotlight, the group digs into some of the high caliber private companies emerging in biotech. The group also covers data updates and related stock price reactions from Summit (the company’s shares tripled after cancer treatment data), Insmed (shares rocketed following Phase 3 trial results for the company’s experimental airway disease drug), Biohaven (its protein-degrader drug falls short of investor expectations), and Roivant’s update on FcRn development plans. In a lively discussion, the hosts share varying viewpoints on whether a CEO should respond or comment to criticism on social media, plus they look ahead to ASCO, and more. This episode aired on May 31, 2024.
On this week’s Biotech Hangout, hosts Daphne Zohar, Josh Schimmer, Yaron Werber, Luba Greenwood and Dawn Bell start the show with a look at the XBI and M&A activity from the week, including multiple deals topping over $1 billion. The hosts highlight a few of these big transactions, including Biogen acquiring Hi-Bio for $1.15 billion, Merck acquiring Eyebio for $1.3 billion, J&J buying Yellow Jersey for $1.25 billion, and Novartis buying out Mariana for $1 billion, among others. With private acquisitions in the spotlight, the group digs into some of the high caliber private companies emerging in biotech. The group also covers data updates and related stock price reactions from Summit (the company’s shares tripled after cancer treatment data), Insmed (shares rocketed following Phase 3 trial results for the company’s experimental airway disease drug), Biohaven (its protein-degrader drug falls short of investor expectations), and Roivant’s update on FcRn development plans. In a lively discussion, the hosts share varying viewpoints on whether a CEO should respond or comment to criticism on social media, plus they look ahead to ASCO, and more. This episode aired on May 31, 2024.
57 min